Key result
Angiopoietin-2 (ANG2) was the only biomarker capable of predicting severity, course, and outcome of late onset ARDS in 101 febrile critically ill patients, 48% of whom had ARDS at baseline.
Why the study?
Do serial inflammatory biomarkers predict the severity, course, and outcome of late onset ARDS in critically ill patients with new-onset fever?
Observational (n=101)
Do serial inflammatory biomarkers predict the severity, course, and outcome of late onset ARDS in critically ill patients with new-onset fever?
ANG2 is a specific biomarker capable of predicting severity, monitoring course, and predicting outcome of late onset ARDS in febrile critically ill patients.
No takes yet. Share an insight, caveat, or question.
ANG2 may aid ARDS prognostication in febrile critically ill patients; leaves open prospective validation before clinical adoption.
Hoeboer et al. (2015) conducted an observational in Late onset acute respiratory distress syndrome (ARDS) (n=101). Inflammatory biomarkers (ANG2, PTX3, IL-6, PCT, proADM) was evaluated on Severity, course and outcome of late onset ARDS. Angiopoietin-2 (ANG2) was the only biomarker capable of predicting severity, course, and outcome of late onset ARDS in 101 febrile critically ill patients, 48% of whom had ARDS at baseline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: